Bleeding Disorders

Hackner, Susan G.; Rousseau, Alexandre Fontaine

doi:10.1016/b978-1-4557-0306-7.00105-7

Cited by 6 publications

(5 citation statements)

References 144 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While PT/aPTT are useful for testing secondary haemostasis, they utilise isolated plasma and provide limited information beyond the basic biochemical properties of these cascades. 62 Similarly, platelet aggregometry measures platelet activation through changes in light transmission through purified samples with a certain degree of transparency, such as washed platelets or platelet-rich plasma. However this technique provides no information on blood coagulation and overall blood clot structure in whole blood as can be achieved in our nanotechnological approach.…”

Section: Resultsmentioning

confidence: 99%

Magnetic coagulometry: towards a new nanotechnological tool for ex vivo monitoring coagulation in human whole blood

Santana-Otero,

Harper,

Telling

et al. 2024

Nanoscale

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Magnetic coagulometry: towards a new nanotechnological tool for ex vivo monitoring coagulation in human whole blood

Santana-Otero,

Harper,

Telling

et al. 2024

Nanoscale

View full text Add to dashboard Cite

show abstract

“…A massive transfusion was defined as a transfusion of blood components greater than the patient's blood volume within a 24-hour period or the transfusion of half the patient's blood volume within 3 hours. 7 Other investigated underlying conditions with a described use of rFVIIa include disseminated intravascular coagulopathy (DIC), thrombocytopathies, warfarin ingestion/therapy, and liver disease. Patients with DIC exhibit marked hemorrhagic complications and may benefit from rFVIIa therapy, but because thrombus formation is also a component of DIC, rFVIIa may potentially exacerbate a hypercoagulable state.…”

Section: Discussionmentioning

confidence: 99%

“…Both patients described in this case report had massive transfusions performed prior to administration of rFVIIa, which may have positively affected their response to the medication. A massive transfusion was defined as a transfusion of blood components greater than the patient's blood volume within a 24‐hour period or the transfusion of half the patient's blood volume within 3 hours 7 …”

Section: Discussionmentioning

confidence: 99%

Use of recombinant human factor VIIa in 2 patients with postoperative noncompressible, abdominal hemorrhage

Zorn

Blong

Walton

2023

J Vet Emergen Crit Care

View full text Add to dashboard Cite

Objective To describe the clinical presentation, clinical course, and successful management of noncompressible, abdominal hemorrhage with recombinant human factor VIIa (rFVIIa) in 2 postoperative patients. Case Summary A 14‐year‐old neutered female Border Terrier and a 9‐year‐old neutered male domestic shorthair were treated with rFVIIa to treat noncompressible abdominal hemorrhage in the postoperative period. The dog presented for a septic abdomen following endoscopic intestinal biopsies 10 days prior and was found to have a jejunal perforation along with a fractured liver lobe and hepatic lymphoma at the time of exploratory laparotomy. The cat presented for a spontaneous hemoabdomen associated with hepatic amyloidosis. Clinically significant hemorrhage occurred in the perioperative and postoperative period and both patients received massive transfusions and antifibrinolytic therapy. Despite these interventions, the patients continued to have ongoing abdominal hemorrhage and surgical attempts at hemostasis were not attempted due to the friable nature of the liver at the time of surgery. Both patients received rFVIIa intravenously every 3 hours at a dose between 70 and 90 μg/kg as indicated by the clinical picture, which subsequently decreased transfusion requirements. New or Unique Information Provided This case report describes the use of rFVIIa in a cat and a dog with severe, noncompressible abdominal hemorrhage in combination with standard hemostatic interventions.

show abstract

“…Dogs were categorised as having DIC if at least three of the following criteria were met at the time of admission 11 : decreased platelet count (<200×10 9 /l), prolonged prothrombin time (PT >10 seconds), prolonged activated partial thromboplastin time (aPTT >20 seconds), prolonged thrombin time (TT >25 seconds), reduction of fibrinogen concentration (<1.5 g/l), increased fibrinogen and fibrin(ogen) degradation products (FDPs) concentration (>5 µg/ml) or increased D‐dimer concentration (>0.8 µg/ml). Dogs were excluded from the study (1) if anticoagulants (unfractionated or low‐molecular‐weight heparin or antiplatelet medications (aspirin or clopidogrel)) were given during the month preceding admission, (2) if all blood parameters could not be assessed at the time of admission (especially for dogs presenting to the ICU during the overnight hours when TEM analysis was not available) or (3) if no definitive diagnosis was obtained.…”

Section: Methodsmentioning

confidence: 99%

Prospective assessment of the diagnostic and prognostic utility of rotational thromboelastometry for canine disseminated intravascular coagulation

et al. 2018

View full text Add to dashboard Cite

This study compared the haematological, haemostatic and thromboelastometric (TEM) parameters between dogs with and without suspected disseminated intravascular coagulation (DIC). Seventy-six dogs with a medical condition known to predispose to DIC were prospectively included in the study. Thirty-eight dogs (50 per cent) presented with haemorrhagic diatheses. DIC was diagnosed in 32 dogs (42 per cent). Thirty-five dogs (46 per cent) had a normal TEM profile, 25 dogs (33 per cent) had a hypercoagulable profile and 16 dogs (21 per cent) had a hypocoagulable profile. Except for the lysis parameters, all TEM parameters were significantly correlated with the presence of DIC in univariate and multivariate analyses. Mortality rates were significantly higher in dogs with DIC (50 per cent) than in dogs without DIC (27 per cent, P=0.043; OR 2.667, 95 per cent CI 1.049 to 6.701), and mortality rates were significantly higher in dogs with a hypocoagulable profile (69 per cent) than in dogs with a hypercoagulable (24 per cent, P=0.017; OR 4.800, 95 per cent CI 1.241 to 16.220) or a normal profile (31 per cent, P=0.046; OR 3.429; 95 per cent CI 1.006 to 11.470). All TEM parameters were significantly associated with mortality in univariate and multivariate analyses. Thromboelastometry appears to be a valuable tool for the diagnosis and prognosis of dogs with suspected DIC, especially those with a hypocoagulable profile that was associated with increased risk of death and increased risk of haemorrhagic diatheses.

show abstract

Bleeding Disorders

Cited by 6 publications

References 144 publications

Magnetic coagulometry: towards a new nanotechnological tool for ex vivo monitoring coagulation in human whole blood

Magnetic coagulometry: towards a new nanotechnological tool for ex vivo monitoring coagulation in human whole blood

Use of recombinant human factor VIIa in 2 patients with postoperative noncompressible, abdominal hemorrhage

Prospective assessment of the diagnostic and prognostic utility of rotational thromboelastometry for canine disseminated intravascular coagulation

Contact Info

Product

Resources

About